The Goldman Sachs Group Cuts GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $81.00

GE HealthCare Technologies (NASDAQ:GEHC) had its price target decreased by The Goldman Sachs Group from $97.00 to $81.00 in a research report report published on Thursday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other research analysts also recently issued reports on the company. Jefferies Financial Group lifted their price target on GE HealthCare Technologies from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Piper Sandler lifted their price target on GE HealthCare Technologies from $91.00 to $94.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Citigroup cut their price target on GE HealthCare Technologies from $88.00 to $84.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of GE HealthCare Technologies in a research note on Monday, December 29th. Finally, UBS Group downgraded GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lifted their price target for the stock from $73.00 to $77.00 in a research note on Thursday, January 15th. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $90.75.

GE HealthCare Technologies Trading Up 0.4%

NASDAQ:GEHC opened at $73.18 on Thursday. The company has a market capitalization of $33.39 billion, a PE ratio of 16.05, a price-to-earnings-growth ratio of 1.61 and a beta of 1.17. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 0.91. GE HealthCare Technologies has a 52-week low of $59.95 and a 52-week high of $89.77. The stock has a fifty day simple moving average of $76.14 and a 200-day simple moving average of $77.93.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, February 4th. The company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.04. The business had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.60 billion. GE HealthCare Technologies had a return on equity of 21.35% and a net margin of 10.11%.The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.45 EPS. GE HealthCare Technologies has set its FY 2026 guidance at 4.950-5.150 EPS. On average, equities research analysts expect that GE HealthCare Technologies will post 4.68 earnings per share for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Friday, April 3rd will be given a dividend of $0.035 per share. This represents a $0.14 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Thursday, April 2nd. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.07%.

Institutional Trading of GE HealthCare Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GEHC. Auto Owners Insurance Co increased its position in GE HealthCare Technologies by 9,525.4% during the 4th quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after purchasing an additional 33,629,559 shares in the last quarter. Norges Bank purchased a new stake in GE HealthCare Technologies during the 4th quarter worth about $596,024,000. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in GE HealthCare Technologies during the 4th quarter worth about $533,655,000. Capital Research Global Investors increased its position in GE HealthCare Technologies by 25.0% during the 3rd quarter. Capital Research Global Investors now owns 24,972,556 shares of the company’s stock worth $1,875,400,000 after purchasing an additional 4,998,154 shares in the last quarter. Finally, Cynosure Group LLC increased its position in GE HealthCare Technologies by 21,045.4% during the 4th quarter. Cynosure Group LLC now owns 4,365,462 shares of the company’s stock worth $358,055,000 after purchasing an additional 4,344,817 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Stories Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: GE HealthCare announced integration of its bkActiv intraoperative ultrasound with Medtronic’s Stealth AXiS platform to provide live neurosurgery imaging — a commercial tie-up that could increase adoption of GEHC systems in robotic/precision cranial procedures. GEHC Unifies bkActiv With Stealth AXiS for Live Neurosurgery Imaging
• Positive Sentiment: Trade press coverage highlights the same intraoperative ultrasound integration with Medtronic’s surgical navigation robot, reinforcing the commercial narrative and potential workflow wins in the OR. This supports revenue-growth expectations for imaging solutions. GE HealthCare integrates intraoperative ultrasound with Medtronic Stealth AXiS surgical robot platform
• Positive Sentiment: Multiple bullish analyst pieces (including Zacks) are promoting GEHC as a top long‑term healthcare stock, which can support investor sentiment and buying interest among growth‑oriented funds. Why GE HealthCare Technologies (GEHC) is a Top Stock for the Long-Term
• Neutral Sentiment: Goldman Sachs reiterated a Buy rating but lowered its price target from $97 to $81 — signaling continued confidence in GEHC’s fundamentals while trimming expected near‑term upside. That combination can sustain demand but cap immediate upside. GE HealthCare Technologies price target lowered by Goldman Sachs
• Neutral Sentiment: Reported short‑interest data for April is effectively meaningless (shows zero/NaN), so there’s no clear short‑pressure signal to explain price movement today.
• Negative Sentiment: A critical review published by American Banking News raises questions about the name and may feed short‑term skepticism among some retail/institutional investors. GE HealthCare Technologies & Glucose Health Critical Review

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.